Neurizon Therapeutics Limited has released a press release.
MND Trial Successfully Completes 3rd Patient Cohort
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Canine Trial Update
- Results show MPL suppresses biomarkers associated with MND
- Louie the Beagle surpasses one year on MPL
- MND Biomarkers and Pharmacodynamics Results
- Motor Neurone Disease Phase 1/2 Clinical Trial Update
Later from Neurizon Therapeutics
- Epichem enters voluntary liquidation
- Cohort 3 Pharmacokinetics in MND Patients Completed
- Additional Phase 1 data suggest MPL may inhibit MND
- Chief Executive Officer Appointment
- Appendix 4E & Full Year Statutory Accounts
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics